An association between parameters of liver blood flow and percentage hepatic replacement with tumour. by Hunt, T. M. et al.
The Macmillan Press Ltd., 1989
An association between parameters of liver blood flow and percentage
hepatic replacement with tumour
T.M. Hunt, A.D.S. Flowerdew, A.J. Britten', J.S. Fleming', S.J. Karran & I. Taylor
University Surgical Unit and 'Department of Nuclear Medicine, Southampton General Hospital, Tremona Road, Southampton,
Hants S09 4XY, UK.
Summary The extent of hepatic replacement with tumour is a significant prognostic factor in patients with
liver metastases. Measuring the percentage hepatic replacement (PHR) accurately is difficult, but is important
for both patient management and clinical trial evaluation. This study correlates haemodynamic indices
obtained by dynamic liver scintigraphy (DLS) with estimates of PHR made from isotope scan, ultrasound,
CT scan and laparotomy in 45 patients with established colorectal liver metastases and 21 controls who also
underwent DLS. There was a significant reduction in the mesenteric fraction (MF) in the group of patients
with metastases compared to the controls (P<0.001), and also a significant trend for progressive reduction in
the MF with increasing PHR. A significant rise in an index of total hepatic arterial blood flow was also
demonstrated with increasing PHR. These results are important with current interest in regional hepatic
arterial therapy, and may prove of clinical value for prediction or monitoring of response to therapy.
It is becoming increasingly apparent that a reasonably
accurate assessment of the extent of hepatic replacement
with tumour is required to determine appropriate patient
management. However, the extent of hepatic replacement is
difficult to measure accurately with available imaging
techniques. Estimates can be expressed as the percentage
hepatic replacement (PHR). PHR estimates made at
laparotomy (Bengtsson et al., 1981; Cady & Oberfield, 1974;
Daly et al., 1985), or from isotope imaging (Cady &
Oberfield, 1974; Mansfield et al., 1969), angiography
(Lundstedt et al., 1985; Ekberg et al., 1986) or a mixture of
imaging techniques (Little & Hollands, 1987) all demonstrate
an inverse relationship with patient survival. Tumour extent
as measured by the PHR is therefore important for
prognosis and also for the interpretation of clinical trials.
Dynamic liver scintigraphy (DLS) is an imaging technique
used to investigate the haemodynamics of hepatic blood flow
(Fleming et al., 1983). The purpose of the present study was
to correlate the results of DLS with the PHR assessments
obtained from ultrasound, computed tomography (CT),
static isotope imaging and laparotomy in a series of patients
with colorectal liver metastases.
Patients and methods
Forty-five patients with established colorectal liver
metastases were investigated with DLS. Liver imaging was
obtained by static isotope scan (43 cases), ultrasonography
(43) and CT (34) in order to estimate the PHR. Operative
assessment of PHR was performed in 26 patients.
Visual assessment of PHR was made for each method by a
specialist in that field, or the surgeon at laparotomy, without
knowledge of the estimates made by any other method.
Estimates were classified as: stage 1 <25%; stage 2 25-50%;
stage 3 >50%.
Twenty-one controls also underwent DLS. Four were
healthy volunteers and 17 were patients who had undergone
resections for primary colorectal cancer and in whom
investigations revealed no evidence of liver metastases. All
remained disease free for at least 18 months after
investigation.
Dynamic liver scintigraphy
The technique and analysis of dynamic liver scintigraphy
have previously been described and validated (Fleming et al.,
1981, 1983). Each study is performed on a fasted patient,
positioned supine under a large field of view gamma-camera.
A rapid intravenous bolus injection of approximately
150MBq. 99Tcm-sulphur colloid (Technecoll, Mallinckrodt
Ltd) is given and anterior images acquired on computer to
include the heart, liver, spleen and both kidneys. The study
is divided into two stages: the first 40 seconds comprises
80 x 0.5 s images and this is followed by a further 60 images
at 15s intervals. The first stage acquires images of the first
pass of colloid through the liver from which the relative
arterial and mesenteric venous components of hepatic blood
flow are determined. The fraction of the total contributed by
the mesenteric venous circulation is the mesenteric fraction
(MF). The second stage of the study measures the rate of
colloid clearance from the blood (k) and this is an index of
total reticuloendothelial blood flow.
For the purposes of this study, the mesenteric fraction,
colloid clearance rate and liver:spleen (L/S) ratio were all
determined, from which the total hepatic arterial blood flow
index (Kart) was also calculated. The MF was calculated as
previously described (Fleming et al., 1983).
Colloid clearance rate
The colloid clearance rate from the blood (k) was determined
in 19 control subjects and 44 patients from the time-activity
curve of a region of interest (ROI) constructed around the
whole liver from the final image of the study. Each point on
the curve between I and 8min was subtracted from the mean
plateau between 14 and 15min. k was derived using least
squares regression on the logarithm of the subtracted curve
(Miller et al., 1979).
Liver:spleen ratio
The liver:spleen (L/S) ratio was determined from the
activities recorded in the whole liver and spleen in the final
anterior image of the dynamic study and also a 30s static
posterior image that was acquired on completion of the
dynamic study. The L/S ratio is given as the ratio of the
geometric means of the anterior and posterior counts in the
liver and spleen. Unfortunately the posterior image, and
therefore the L/S ratio, was only acquired in 14 controls and
40 of the patients with metastases.
Total hepatic arterial bloodflow index (Kart)
An index of total hepatic arterial blood flow to both the
liver and tumour (Kar.) can be calculated from the colloid
Correspondence: T.M. Hunt.
Received 25 June 1988, and in revised form, 7 October 1988.
Br. J. Cancer (1989), 59, 410-414BLOOD FLOW AND HEPATIC REPLACEMENT 411
clearance rate (k), L/S ratio and mesenteric fraction (MF) as
follows:
1.0
0.9s
Kart =k x L/S+1 x (1-MF) [1]
0.8
See the Appendix for the derivation of this equation. All the
necessary values for the calculation of Kar, were available in
13 controls and 40 patients with metastases.
Isotope imaging
This was performed on completion of the dynamic liver
study, using the same gamma-camera. Standard anterior,
posterior, left and right lateral 30s static views were
obtained.
Ultrasonography
Ultrasound was performed using a Philips Sonodiagnost
7000 combined static/real-time machine initially and later a
Siemens SL2 real-time unit. Multiple longitudinal and trans-
verse sections were obtained when possible, but a more
limited series of oblique intercostal sections was recorded
when access was poor.
Computerised tomography
CT was performed using a Siemens Somatom DR2 whole
body scanner. 700ml of 2% iodinated oral contrast medium
was given 20-30Min before scanning with 8mm slices taken
at 1.6cm intervals. Then 50ml of iodinated contrast medium
was given intravenously as a bolus. This was followed by
another 50ml as a rapid infusion, further scanning being
performed using 8mm slices at 1.0cm intervals.
Statistics
Statistical analysis of the results was performed using the t
test for the MF and Ka,, of the whole group of patients with
metastases versus controls. The significances of the trends
with PHR staging were determined using the analysis of
variance with linear contrast.
Results
Mesenteric fraction
The mean MF of the group of patients with metastases
(0.51+0.03 s.e.m.) was significantly lower than for the
control group (0.65+0.02 s.e.m.) (P<0.001, Figure 1).
The patients with metastases were then subdivided by an
overall 'consensus' PHR grouping obtained as a simple
average of the stages given by the individual techniques
available in each case (Figure 2). A significant trend for
decreasing MF with increasing PHR is seen by analysis of
variance with linear contrast (P<0.0001).
Because of the variation in PHR estimations that can
occur using different methods, each technique used has also
been investigated individually (Table I). A significant trend
for decreasing MF with increasing PHR exists in each case.
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Figure 1 Mesenteric fraction (MF) of controls (n =21) and
patients with metastases (n=45). Mean values and 95% confi-
dence intervals of the mean are marked. P value by t test.
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Figure 2 Mesenteric fraction (MF) of controls and patients sub-
divided by overall PHR stage. Stage 1 (n = 16); stage 2 (n=9);
stage 3 (n=20). P value for progressive change with PHR by
analysis of variance with linear contrast.
Total hepatic arterial bloodflow index (Kar,)
Neither the colloid clearance rate (k) (Figure 3) nor the L/S
ratio (Figure 4) demonstrated any significant change with
PHR, and there were no significant differences between any
of the groups. However, the mean Kart was significantly
higher in the group of patients with metastases than in the
control group (0.109 +0.006 s.e.m. versus 0.078 +0.008;
P<0.005; Figure 5).
The Kar, subdivided by overall PHR group also showed a
significant trend, K.,, increasing with PHR staging
(Figure 6).
Discussion
A reduction in the MF of specific.tumour regions of interest
compared to neighbouring 'normal' liver regions in the same
patients with hepatic tumours, or to liver regions in a
control group has previously been reported (Flowerdew et
al., 1987). An increased arterial index for the maximal liver
ROI that can be investigated has also been reported in
tumour-bearing liver (Leveson et al., 1985). We have demon-
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Table I Mean values of MF (± Is.d.) for controls and PHR stages as estimated by CT,
isotope, ultrasound or surgery
PHR stage
Controls
0.65+0.10 0.59+0.12
0.05<P<0.1
n= 13
0.65+0.10 0.60+0.11
0.05<P<0.1
n= 16
0.65+0.10 0.58+0.13
0.05<P<0.1
n=16
0.65+0.10 0.61+0.13
P=0.18
n=12
2
0.51 +0.14
P<0.02
n=5
0.55 +0.20
P<0.02
n = l1
0.49+0.15
P<0.005
n=8
0.49 +0.19
P<0.01
n=5
Significance
of trend
3 with PHR (P)
0.44+0.16
P<0.0001
n=16
0.38+0.13
P<0.0001
n=16
0.46+0.19
P<0.0001
n=19
0.49+0.16
p<0.005
n=9
<0.0001
<0.0001
<0.001
<0.001
P values given for each stage compared to controls (t test). Overall P value for progressive
change with PHR by analysis of variance with linear contrast. n=number of patients in each
PHR stage by each method.
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Figure 3 Colloid clearance rate (k) for controls (n 19) and
patients (n=44) by PHR stage. Means and 95% CI marked
showing no significant differences between any of the groups or
any progressive change with PHR.
strated that the MF of the maximal liver ROI in a group of
patients with established colorectal liver metastases is also
significantly reduced compared to controls (P<0.001), as
might be expected from the previous studies. In addition
there is a significant trend for progressive reduction in the
MF with increasing tumour extent as determined by PHR
stage.
The derivation of an index of total hepatic arterial flow
(Kart) allows us to conclude that although the total reticulo-
endothelial cell flow (k) does not change, the total absolute
hepatic arterial flow (to functioning liver and tumour)
increases with increasing tumour extent. As noted in
the Appendix, care must be taken when interpreting indices
from DLS using colloid in the presence of tumour tissue. In
particular, it is not possible to specify whether arterial flow
to normal functioning liver alone has changed.
Figure 4 Liver:spleen (L/S) ratio for controls (n = 14) and
patients (n=40) by PHR stage. Means and 95% CI marked
showing no significant differences between any of the groups.
These results are compatible with the following hypotheses
of the haemodynamic development of tumours. First,
constant flow to normal liver may be maintained with an
additional arterial flow to tumour tissue. Secondly, the
arterial increase may represent increased flow to normal and
tumour tissue. This may result from a pressure-induced
decrease in portal venous flow as tumour size increases, with
a compensatory increase in arterial flow to normal liver in
addition to arterial tumour perfusion.
Although a highly significant trend exists for MF reduc-
tion and Kart increase with PHR, there is poor separation
between groups. The spread of values within each PHR
grading is likely to be affected by variability in the measure-
ment of the haemodynamic indices, the limitations in deter-
mining the physical extent of tumour (Lundstedt et al., 1985;
Hunt et al., 1989) and individual variation in the features of
tumours even of a given size. For example, the relative
position of tumour within the liver as a whole will affect the
proportion present in the maximal ROI that can be studied
and may or may not cause a degree of portal venous
obstruction.
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All increase in absolute hepatic arterial blood flow is
significant when considering intra-arterial therapy regimes. It
is possible that both tumour growth and prediction of
response to therapy may be more closely related to haemo-
dynamic factors than to physical size estimates. The poor
separation between groups prevents the recommendation of
DLS for staging disease, but progressive changes in haemo-
dynamic values on serial measurements may be of great
value in individual cases. Further work is in progress to
determine the value of haemodynamic indices derived from
DLS in evaluating tumour growth and response to therapy.
Appendix
Here we describe the derivation of the expression for Kart
(equation [1]). The discussion is based on the model shown
in Figure 7. In the presence of tumour, the blood flow via
the arterial route can be considered in two separate parts -
that supplying the liver (QLA) and that supplying the tumour
(QT). If it is assumed, for simplicity, that the extraction
efficiencies for colloid in the liver and spleen are 100%, in
tumour 0%, and that the bone marrow flow approximates to
zero, then the colloid clearance rate (k) is given by:
Controls Patients
with
metastases
Figure 5 K,at for controls (n= 13) and patients with metastases
(n=40). Mean values and 95% CI marked. P value by t test.
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k=QLA+ QM + QS [Al]
where QM and QS are the blood flows of the mesenteric and
splenic arteries respectively (Walmsley et al., 1987). All blood
flows are expressed as fractions of blood volume per unit
time. Since the final amounts of colloid in the liver and
spleen (L and S respectively) are proportional to the
appropriate effective blood flows, then:
L/S =(QM +QLA)/QS [A2]
Thus, from equations [Al] and [A2], a measure of liver
blood flow can be assessed:
QM+QLA =k x L/S [A3]
In the first pass study, the interpretation of the mesenteric
fraction will be affected by the presence of tumour in the
liver. The amount of colloid in the liver at the end of the
arterial phase will be proportional to the total flow arriving
via the arterial route (QLA+QT). The amount of colloid at the
end of the portal phase will be proportional to QM+QLA.
There is no contribution to colloid in the liver via the splenic
component of portal flow since this is removed by the spleen.
The colloid arriving via the tumour component of arterial
flow has a transient presence in the liver ROI since it will
not be extracted by the tumour. It is assumed that all this
colloid is present in the liver region at the end of the arterial
Controls <25% 25-50%
PHR
Figure 6 Kart for controls and patients sub-divided by PHR
stage. Stage 1 (n=14); stage 2 (n=9); stage 3 (n=17). P value
for progressive change with PHR by analysis of variance with
linear contrast.
The PHR is a recognised prognostic factor and is
therefore important for evaluation of clinical trials, and
potentially to monitor any response to therapy. This study
shows that haemodynamic indices determined by DLS
correlate with PHR as assessed by ultrasound, isotope
imaging, CT scanning and laparotomy collectively or indi-
vidually. The correlation between the different methods of
assessing PHR has previously been reported in 56 patients
which include the 45 presented in this study (Hunt et al.,
1989).
QLA, 0QBM
Figure 7 Schematic model of the distribution of an intra-
venously injected colloid. (QLA=liver tissue arterial blood flow;
QT = tumour arterial blood flow; QM = mesenteric venous flow;
Qs=splenic artery flow.)
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phase but that none is left at the end of the portal phase.
Thus the measured arterial fraction (AF) will be given by:
AF-=Q+ +QT. [A4]
Here we assume that the liver ROI is representative of the
whole. Since (AF) is equal to (1-MF) equations [A3] and
[A4] combine to give:
L/S
Kart=QLA+QTkX L/S+1 x(1-MF). [A5]
A number of assumptions have been made in this argu-
ment which would lead to errors in using the equations to
find accurate absolute values for blood flow. However, the
assessment of Kart in this way does produce a useful index of
the total arterial blood flow to both liver and tumour.
We are grateful to the Cancer Research Campaign for funding these
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